苯那普利联用罗格列酮治疗糖尿病肾病的临床观察

目的:观察苯那普利联用罗格列酮治疗糖尿病肾病(diabetic nephropathy,DN)的临床效果.方法:将本科58例4期DN患者随机分为治疗组(32例)和对照组(26例).两组患者予以一般治疗、胰岛素治疗及口服苯那普利.治疗组联用罗格列酮4 mg/d,共3个月.治疗前后分别测血压(SBP/DBP)、Upr、UAE、BUN、Ccr、FG、血β2-MG、尿β2-MG.结果:两组分别在治疗前后检测SBP、DBP、Upr、UAE、Ccr、尿β2-MG差异有统计学意义(P＜0.05);治疗后治疗组上述指标与对照组比较差异有统计学意义(P＜0.05).结论:苯那普利联用罗格列酮治疗DN在减少尿蛋白、改善肾功能方面明显优于单用苯那普利,提示两药联用在延缓DN进展方面能够发挥各自的优势,起到协同作用.

The Clinical Observation of Benazepril Combined with Rrosiglitazone in Patients with Diabetic Nephropathy

Objective:To evaluate the clinical efficacy of benazepril combined with rosiglitazone in patients with diabetic nephropathy(DN).Methods: 58 patients with stage IV DN were randomLy allocated to a therapeutic group(n=32) or a control group(n=26).Patients in the two groups were given the same regimen,such as common treatment,insulin injection and oral benazepril.The therapeutic group were added with oral rosiglitazone 4 mg daily for 3 months.Before and after treatment,levels of SBP/DBP,Upr,UAE,BUN,Ccr,FG,blood beta2-MG,urine beta2-MG were detected respectively.Results: In both groups,statistically significant differences in levels of SBP,DBP,Upr,UAE,Ccr,urine beta2-MG were observed before and after treatment (P<0.05).Post-treatment improvements in these parameters were also recorded in the therapeutic group as compared with controls(P<0.05).Conclusion: Benazepril combined with rosiglitazone in treatment of DN showed better effectiveness in reducing albuminuria and improving renal function than benazepril alone,suggesting that combination of the two drugs can be synergistic against DN development.